

MEDISTEP HEALTHCARE LIMITED

CIN: U21009GJ2023PLC141841

Balance Sheet

As at March 31, 2024

All amounts in INR Thousands, unless otherwise stated

Particulars	Note	As at March 31, 2024
I. EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	3	48,994.40
Reserves and Surplus	4	73,087.61
		1,22,082.01
Non-current liabilities		
Long-Term Provisions	5	66.39
		66.39
Current liabilities		
Short-Term Borrowings	6	3,261.63
Trade Payables		
total outstanding dues of micro and small enterprises	7	-
total outstanding dues of creditors other than micro	7	14,095.24
Other current liabilities	8	189.27
Short-Term Provisions	9	9,885.00
		27,431.14
TOTAL EQUITY AND LIABILITIES		1,49,579.54
II. ASSETS		
Non-current assets		
Property, Plant and Equipment and Intangible Assets		
Property, Plant and Equipment	10	1,728.99
Deferred Tax Assets (Net)	11	10.27
Other non-current assets	12	55.00
		1,794.26
Current assets		
Current investments	13	15.00
Inventories	14	9,287.54
Trade Receivables	15	1,37,508.97
Cash and Cash Equivalents	16	97.54
Other current assets	17	876.23
		1,47,785.28
TOTAL ASSETS		1,49,579.54

The accompanying notes are an integral part of the Financial Statements

As per our report of even date attached

For RUBI AGRAWAL & ASSOCIATES

Chartered Accountants

Firm Regn No : 0020722C

For and on behalf of Board of Directors



Place : Ahmedabad

Date : August 08, 2024

UDIN: 24158759BKAMPE8046

RUBI AGRAWAL

F.R.N. 020722C

Membership No : 158759

Girdhari Lal Prajapat
Managing Director
DIN : 09513249

Place : Ahmedabad

Date : August 08, 2024

Vipul Gobarbhay Dabhi
Director
DIN : 09513250

Place : Ahmedabad

Date : August 08, 2024



MEDISTEP HEALTHCARE LIMITED

CIN: U21009GJ2023PLC141841

Statement of Profit And Loss

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

Particulars	Note	Year ended March 31, 2024
INCOME		
Revenue From Operations	18	3,15,949.54
Total Income		3,15,949.54
EXPENSES		
Cost of Materials Consumed	19	2,82,854.48
Changes in inventories of finished goods, work-in-progress and stock-in-trade	20	(9,287.54)
Employee Benefits Expense	21	1,309.65
Finance costs	22	598.00
Depreciation and Amortisation Expense	23	208.05
Other Expenses	24	1,343.48
Total Expenses		2,77,026.12
Profit before tax		38,923.42
TAX EXPENSES		
Current Tax	25	9,937.68
Deferred Tax	25	(10.27)
PROFIT FOR THE YEAR		28,996.01
EARNINGS PER EQUITY SHARE		
Basic (Face value of Rs.10 each)	26	5.92
Diluted (Face value of Rs.10 each)	26	5.92

The accompanying notes are an integral part of the Financial Statements
As per our report of even date attached

For RUBI AGRAWAL & ASSOCIATES

Chartered Accountants

Firm Regn No : 0020722C



Rubi Agrawal
RUBI AGRAWAL
Partner
Membership No : 158759

Place : Ahmedabad

Date : August 08, 2024

UDIN: 24158759BKAMPE8046

For and on behalf of Board of Directors

Girdhari Lal Prajapat
Managing Director
DIN : 09513249

Place : Ahmedabad

Date : August 08, 2024

Vipul Gobarbhai Dabhi
Director
DIN : 09513250

Place : Ahmedabad

Date : August 08, 2024



MEDISTEP HEALTHCARE LIMITED

CIN: U21009GJ2023PLC141841

Statement of Cash Flows

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

Particulars	Year ended March 31, 2024
A. CASH FLOW FROM OPERATING ACTIVITIES	
Profit before tax	38,923.42
Adjustments for :	
Interest expense	528.68
Provision for Long Term Employee Benefits	66.44
Depreciation and Amortization Expense	208.05
Operating Profit Before Working Capital Changes	39,726.59
Increase / (Decrease) in Trade Payables	14,095.24
Increase / (Decrease) in Other liabilities	189.27
Increase / (Decrease) in Provisions	60.50
Decrease / (Increase) in Inventories	(9,287.54)
Decrease / (Increase) in Trade Receivables	(1,37,508.97)
Decrease / (Increase) in Other assets	(931.23)
Cash generated from / (used in) Operations	(93,656.14)
Income taxes paid	(113.23)
Net Cash generated from / (used in) Operating Activities	(93,769.37)
B. CASH FLOW FROM INVESTING ACTIVITIES	
Purchase of Property, Plant and Equipment and Intangible Assets	(1,937.04)
Purchase of Current investments	(15.00)
Net Cash generated from / (used in) Investing Activities	(1,952.04)
C. CASH FLOW FROM FINANCING ACTIVITIES	
Proceeds from issue of Share capital	93,086.00
Proceeds from Short-Term Borrowings	3,261.63
Interest paid	(528.68)
Net Cash generated from / (used in) Financing Activities	95,818.95
Net Increase / (Decrease) In Cash and Cash Equivalents	97.54
Cash and Cash Equivalents at the Beginning	-
Cash and Cash Equivalents at the End	97.54

The accompanying notes are an integral part of the Financial Statements

As per our report of even date attached

For RUBI AGRAWAL & ASSOCIATES

Chartered Accountants

Firm Regn No : 0020722C



RUBI AGRAWAL

Partner

Membership No : 158759

Place : Ahmedabad

Date : August 08, 2024

UDIN: 24158759BKAMPE8046

For and on behalf of Board of Directors

Girdhari Lal Prajapat

Managing Director

DIN : 09513249

Place : Ahmedabad

Date : August 08, 2024

Vipul Gobarbhai Dabhi

Director

DIN : 09513250

Place : Ahmedabad

Date : August 08, 2024



MEDISTEP HEALTHCARE LIMITED

CIN: U21009GJ2023PLC141841

Notes to the Financial Statements

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

1. General Information

MEDISTEP HEALTHCARE LIMITED (the 'Company') is a Public Limited Company, domiciled in India with its registered office located at 05, S.No-245/B, Plot-19, T.P.S.56, Freeway Trade Centre, Nr. A-ONE Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad. The Registration Number of the Company is U21009GJ2023PLC141841. The Company is engaged in the business of Trading of Pharmaceutical & Surgical products and Trading & Manufacturing of Nutraceuticals and Intimate care & hygiene products.

2. Significant Accounting Policies

Basis of Preparation of Financial Statements

The Financial Statements of the Company have been prepared and presented in accordance with the Generally Accepted Accounting Principles in India ('Indian GAAP'). It comprises the Accounting Standards notified u/s 133 read with section 469 of the Companies Act, 2013. The accounting policies have been framed, keeping in view the fundamental accounting assumptions of Going Concern, Consistency and Accrual, and also the basic considerations of Prudence, Substance over form, and Materiality. Based on the nature of products and the time between acquisition of assets and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current or non-current classification of assets and liabilities. These financial statements have been prepared on historical cost basis except certain items like Financial Leases and Defined Benefit Plans are measured at fair value.

Use of Estimates

The preparation of financial statements requires the management to make certain estimates and assumptions that affect the amounts reported in the financial statements and notes thereto. The management believes that these estimates and assumptions are reasonable and prudent but the actual results may differ from them. They are reviewed on an on-going basis and any revision to accounting estimates is recognised prospectively in current and future periods. Accounting estimates and assumptions that have a significant effect on the amounts reported in the financial statements include:

- i) Net Realisable value of items of Inventories
- ii) Useful life and Residual value of Property, Plant and Equipment and Intangible Assets
- iii) Defined Benefit obligations
- iv) Deferred Tax asset or liability
- v) Provisions for Trade Receivables
- vi) Other Provisions and Contingencies

Property, Plant and Equipments

Property, plant and equipments are initially recognised at cost. Cost includes purchase price, taxes and duties and other costs directly attributable to bringing the asset to the working condition for its intended use. However, cost excludes duties and taxes wherever credit of such duties and taxes is availed. It is thereafter carried at its cost less accumulated depreciation and accumulated impairment losses, if any.

Depreciation on tangible assets has been provided on "Written Down Value" method in accordance with the provision of Schedule II of the Companies Act, 2013. Depreciation in respect of tangible assets put to use in current year has been charged on pro rata basis. Residual values @ 5% of the cost of assets are provided.

Depreciation and amortization methods, useful lives and residual values are reviewed periodically.

Investments

Long-term investments are valued at cost less provision for diminution in value, if the diminution is other than temporary. Current investments are valued at lower of cost and fair value. Gain or loss arising on the sale of investments is computed as a difference between carrying amount and the proceeds from sale, net of any expenses. Such gain or loss is recognised in the Statement of Profit and Loss.



Inventories

Inventories are valued at the lower of cost and net realisable value. Cost is computed on a 'First In First Out' basis. Cost of raw materials and stores and spares includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. The aforesaid items are valued at net realisable value if the finished products in which they are to be incorporated are expected to be sold at a loss. Cost of finished goods and work-in-progress include all costs of purchases, conversion costs and other costs incurred in bringing the inventories to their present location and condition. The net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to make the sale.

Trade Receivables and Loans and Advances

Trade Receivables and Loans and Advances are presented after making adequate provision for any shortfall in their recovery. The provision and any subsequent recovery is recognised in the Profit and Loss statement. Bad debts are written off when they are identified.

Cash and cash equivalents

All highly liquid financial instruments, which are readily convertible into known amount of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase are considered to be cash equivalents.

Provisions and Contingent Liabilities

A Provision is recognised when the entity has a present obligation as a result of past event and it is probable that an outflow of resources will be required and a reliable estimate can be made of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance Sheet date.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made. A Contingent asset is neither recognised nor disclosed.

Revenue Recognition

Revenue from sale of goods is recognised when control and significant risks and rewards of ownership of the products being sold is transferred to the customer. This is generally fulfilled at the time of dispatch, delivery or upon formal customer acceptance depending on customer terms. Revenue is measured on the basis of contracted price, after deduction of any trade discounts, volume rebates and any taxes or duties collected on behalf of the government such as goods and services tax, etc. Previous experience is used to estimate the provision for such discounts and rebates. Revenue is only recognised to the extent that it is highly probable a significant reversal will not occur. Income from services rendered is recognised based on agreements/arrangements with the customers as the service is performed and there are no unfulfilled obligations. Interest income is recognized on accrual basis, adopting a time proportion method, taking into account the amount outstanding and the rate applicable. Dividend income on investments is accounted for when the right to receive the income is established. Export incentives are recognised on accrual basis to the extent the management is certain of the income.



Employee Benefits

Short-term employee Benefits

Benefits such as salaries, wages and performance incentives are charged to the statement of profit and loss at the actual amounts due in the period in which the employee renders the related service.

Defined Contribution Plans

Payments made to defined contribution plans such as provident and pension fund are charged as an expense based on the amount of contribution required to be made as and when services are rendered by the employees.

Defined Benefit Plans

All defined benefit plans obligations are determined based on valuations, as at the Balance Sheet date, made by independent actuary using the projected unit credit method. Actuarial gains and losses are recognised immediately in the statement of profit and loss. The fair value of the plan assets is reduced from the gross obligation under the defined benefit plan, to recognise the obligation on net basis.

Other Long-term Employee Benefits

Other long-term employee benefits include leave encashment. Leave encashment is recognised as an expense in the statement of profit and loss as and when it accrues on actuarial basis.

Borrowing Cost

Borrowing costs that are directly attributable to the acquisition or construction of qualifying assets are capitalised. Qualifying asset is an assets that necessarily takes substantial period of time to get ready for its intended use. Other borrowing costs are recognised as an expense in the period in which they are incurred.

Taxes on Income

Income tax expense for the year comprises of current tax and deferred tax.

Current tax

Current tax is the estimated amount of tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Minimum Alternate Tax (MAT) is accounted as Current tax when the taxes calculated as per Book profits are greater than the taxes calculated as per normal provisions of Income Tax. Credit for such MAT is availed when the entity is subjected to normal tax provisions in the future. MAT credit Entitlement is recognised as an asset based on the management's estimate of its recoverability in the future.

Earnings per Share

In determining earnings per share, the Company considers the net profit after tax attributable to equity shareholders. The number of shares used in computing basic earnings per share is the weighted average number of equity shares outstanding during the year. The number of equity shares used in computing diluted earnings per share comprises weighted average number of equity shares considered for deriving basic earnings per share and also weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares.



MEDISTEP HEALTHCARE LIMITED
CIN: U21009GJ2023PLC141841
Notes to the Financial Statements

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

3. Share capital

Particulars	As at March 31, 2024
Authorised 1,10,00,000 (P. Y. NIL) equity shares of face value of Rs.10/- each	1,10,000.00
Issued, subscribed and fully paid up 48,99,440 (P.Y. NIL) Equity Shares of face value of Rs. 10/- each fully paid up	48,994.40
Total	48,994.40

Reconciliation of the number of Equity Shares outstanding

Particulars	As at March 31, 2024	
	No. of Shares	Amount
As at the beginning of the year	-	-
Add : Shares Issued during the year	48,99,440	48,994.40
Less : Deductions during the year	-	-
As at the end of the year	48,99,440	48,994.40

Rights, preferences and restrictions attached to shares

The Company has issued only one class of equity shares having a par value of Rs. 10 per share. Each equity shareholder is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, in proportion to their shareholding. Any dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

Equity Shares held by Shareholders holding more than 5% shares

Name of the Shareholder	As at March 31, 2024	
	No. of Shares	% Shares
Hetalben Shankarlal Prajapati	35,58,200	72.62%
Girdhari Lal Prajapat	7,05,900	14.41%
Vipul Gobarbhai Dabhi	6,34,940	12.96%
Total	48,99,040	99.99%

Details regarding number and class of shares for the period of five years immediately preceding March 31, 2024

- a) The company has not allotted any shares as fully paid-up without payment being received in cash.
- b) The company has not allotted any shares as fully paid up bonus shares.
- c) The company has not bought back any of its shares.

Other Details regarding issue of shares

There are no shares reserved for issue under options and contracts / commitments for the sale of shares.
There are no securities convertible into equity or preference shares.
There are no calls unpaid on any shares.
There are no forfeited shares.



Equity Shares held by Promoters or Promoter Group at the end of the year

Promoter Name	As at March 31, 2024	
	No. of Shares	%
Hetalben Shankarlal Prajapati	35,58,200	72.62%
Girdhari Lal Prajapat	7,05,900	14.41%
Vipul Gobarbhai Dabhi	6,34,940	12.96%
Dharmishthaben Dabhi	100	0.00%
Total	48,99,140	99.99%

4. Reserves and Surplus

Particulars	As at March 31, 2024
Securities Premium	
Opening Balance	-
(+) Additions	44,091.60
(-) Deductions	
Closing Balance	44,091.60
Surplus	
Opening Balance	-
(+) Net Profit or (Loss) for the period	28,996.01
Closing Balance	28,996.01
Total	73,087.61

5. Long-Term Provisions

Particulars	As at March 31, 2024
Provision for Gratuity	66.39
Total	66.39

6. Short-Term Borrowings

Particulars	As at March 31, 2024
Secured	
Loans repayable on demand from banks	490.18
Unsecured	
Current maturities of long-term borrowings	2,117.35
Loans from related parties	654.10
Total	3,261.63



7. Trade Payables

Particulars	As at March 31, 2024
Total outstanding dues of micro and small enterprises	-
Total outstanding dues of other than micro and small enterprises	14,095.24
Total	14,095.24

Ageing for trade payables from the due date of payment for each of the category as at March 31, 2024

Particulars	Outstanding for following periods from due date of payment						Total
	Unbilled	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
MSME			-	-	-	-	-
Others			11,038.78	3,056.46	-	-	14,095.24
Disputed dues – MSME			-	-	-	-	-
Disputed dues – Others			-	-	-	-	-
Total	-	-	11,038.78	3,056.46	-	-	14,095.24

8. Other current liabilities

Particulars	As at March 31, 2024
Employee Dues Payable	113.79
TDS Payable	75.48
Total	189.27

9. Short-Term Provisions

Particulars	As at March 31, 2024
Provision for Gratuity	0.05
Provision for Taxation [Net]	9,824.45
Provision for Audit Fees	25.00
Provision for Other Expenses	35.50
Total	9,885.00



MEDISTEP HEALTHCARE LIMITED
CIN : U21009GJ2023PLC141841

Notes to the Financial Statements

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

10. Property, Plant and Equipment and Intangible Assets for 'Current period'

S.No	PARTICULARS	Gross Block as on 01.04.2023	Addition during the period	Deletion	Gross Block as on 31.03.2024	Accumulated Depreciation as on 01.04.2023	Depreciation for the period	Deletion	Accumulated Depreciation as on 31.03.2024	Net Block as on 31.03.2024	Net Block as on 31.03.2023
	Tangible Assets										
1	Furniture and Fixtures	-	243.41	-	243.41	-	47.31	-	47.31	196.10	-
2	Plant and Machinery	-	1,634.98	-	1,634.98	-	149.34	-	149.34	1,485.64	-
3	Vehicles	-	58.65	-	58.65	-	11.40	-	11.40	47.25	-
	Total (A)	-	1,937.04	-	1,937.04	-	208.05	-	208.05	1,729.00	-
	Intangible Assets (B)	-	-	-	-	-	-	-	-	-	-
	Capital WIP (C)	-	-	-	-	-	-	-	-	-	-
	Gross Total (A+B+C)	-	1,937.04	-	1,937.04	-	208.05	-	208.05	1,729.00	-



MEDISTEP HEALTHCARE LIMITED
CIN: U21009GJ2023PLC141841
Notes to the Financial Statements

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

11. Deferred Tax Assets (Net)

Particulars	As at March 31, 2024
Deferred Tax Asset [Net]	10.27
Total	10.27

12. Other non-current assets

Particulars	As at March 31, 2024
Security Deposits	55.00
Total	55.00

13. Current investments

Particulars	As at March 31, 2024
Shares In Kankaria Maningar Co. Op. Bank	15.00
Total	15.00
Aggregate amount of unquoted investments	15.00

14. Inventories

Particulars	As at March 31, 2024
Finished goods, work-in-progress and stock-in-trade	9,287.54
Total	9,287.54

15. Trade Receivables

Particulars	As at March 31, 2024
Unsecured, considered good	1,37,508.97
Total	1,37,508.97



Ageing for trade receivables from the due date of payment for each of the category as at March 31, 2024

Particulars	Outstanding for following periods from Due Date of Payment						Total
	Not Due	Less than 6 months	6 months - 1 years	1 - 2 years	2 - 3 years	More than 3 years	
Undisputed - Considered Good		70,742.05	66,313.63	453.29			1,37,508.97
Undisputed - Considered doubtful							-
Disputed - Considered Good							-
Disputed - Considered doubtful							-
Total	-	70,742.05	66,313.63	453.29	-	-	1,37,508.97

16. Cash and Cash Equivalents

Particulars	As at March 31, 2024
Cash on Hand	75.47
Balances with Banks	22.07
Total	97.54

17. Other current assets

Particulars	As at March 31, 2024
Goods and Services Tax	876.23
Total	876.23



MEDISTEP HEALTHCARE LIMITED
CIN: U21009GJ2023PLC141841
Notes to the Financial Statements

Year ended March 31, 2024

All amounts in INR Thousands, unless otherwise stated

18. Revenue From Operations

Particulars	Year ended March 31, 2024
Revenue from operations Sale of products	3,15,949.54
Total	3,15,949.54

19. Cost of Materials Consumed

Particulars	Year ended March 31, 2024
Raw materials consumed	2,82,854.48
Total	2,82,854.48

20. Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	Year ended March 31, 2024
Opening Inventories Finished goods, work-in-progress and stock-in-trade	-
Closing Inventories Finished goods, work-in-progress and stock-in-trade	9,287.54
Total	(9,287.54)

21. Employee Benefits Expense

Particulars	Year ended March 31, 2024
Salaries and wages	1,243.21
Contribution to provident and other funds	66.44
Total	1,309.65



22. Finance costs

Particulars	Year ended March 31, 2024
Interest expense on Borrowings	528.68
Other Borrowing costs	69.32
Total	598.00

23. Depreciation and Amortisation Expense

Particulars	Year ended March 31, 2024
Depreciation on Property, Plant and Equipment	208.05
Total	208.05

24. Other Expenses

Particulars	Year ended March 31, 2024
Electricity, Power and fuel	185.33
Rent expenses	399.00
Repairs and maintenance	6.87
Professional and consultancy charges	76.40
Printing and stationery	28.23
Telephone and Internet	28.65
Office and Administration	23.44
Freight and forwarding	9.15
ROC Expenses	546.88
Miscellaneous expenses	14.53
Audit Fees	25.00
Total	1,343.48

25. Tax Expenses

Particulars	Year ended March 31, 2024
Current Tax	
Current Year	9,943.97
Deferred Tax	
Origination and reversal of Timing differences	(10.27)



26. Earnings Per Share

Particulars	Year ended March 31, 2024
Earnings attributable to equity shareholders (a)	28,996.01
Weighted average number of equity shares for calculating basic earning per share (b)	48,99,440
Basic Earning per share (a/b) In Rs. (Face value of Rs.10 each)	5.92
Earnings attributable to potential equity shares (c)	
Earnings attributable to equity and potential equity shareholders (d=a+c)	28,996.01
Weighted average number of potential equity shares (e)	48,99,440
Weighted average equity shares for calculating diluted earning per share (f=b+e)	5.92
Diluted Earning per share (d/f) in Rs. (Face value of Rs.10 each)	-

27 Related Party Disclosures

List of all Related Parties

Name of Related Party	Relationship
Girdhari Lal Prajapat	Managing Director
Vipul Gobarbhai Dabhi	Director
Hetalben Shankarlal Prajapati	Director
Medistep Pharmaceuticals Pvt Ltd	KMP holds significant control
Mahadev Medical Store	Proprietorship firm of KMP
Kavyadi Medical Store	Proprietorship firm of KMP's wife
Jagdish Prajapati	Chief Financial Officer

Transactions with Related Parties and the status of Outstanding Balances

Name of Related Party	Nature of Transaction or Balance	Year ended March 31, 2024 Amt in Rs
Girdhari Lal Prajapat	Unsecured Loan taken	1,78,11,999
Girdhari Lal Prajapat	Share Issue through conversion of loan	1,76,45,000
Girdhari Lal Prajapat	Salary	75,862
Medistep Pharmaceuticals Pvt Ltd	Sales	95,90,902
Medistep Pharmaceuticals Pvt Ltd	Purchases	12,65,130
Mahadev Medical Store	Sales	1,61,83,370
Mahadev Medical Store	Purchases	7,56,930
Kavyadi Medical Store	Sales	4,64,46,715
Kavyadi Medical Store	Purchases	42,365
Jagdish Prajapati	Salary	25,000
Vipul Gobarbhai Dabhi	Unsecured Loan taken	1,58,71,000
Vipul Gobarbhai Dabhi	Share Issue through conversion of loan	1,58,71,000
Hetalben Shankarlal Prajapati	Unsecured Loan taken	4,11,87,523
Hetalben Shankarlal Prajapati	Share Issue through conversion of loan	3,99,70,000



28 Other Disclosures

Disclosure requirements as notified by MCA pursuant to amended Schedule III:

- The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- The Company does not have any Benami Property under Prohibition of Benami Property Transactions Act, 1988.
- The Company has not been declared a wilful defaulter by any lender who has powers to declare a company as a wilful defaulter.
- The Company has no Scheme of Arrangement approved by the competent authority specified under Section 230 to 237 of the Companies Act, 2013.

Previous Period figures have been re-grouped / re-classified, wherever necessary, to make them comparable with Current Period's classification.

As per our report of even date attached

For RUBI AGRAWAL & ASSOCIATES

Chartered Accountants

Firm Regn No : 0020722C



Place : Ahmedabad

Date : August 08, 2024

UDIN: 24158759BKAMPE8046

For and on behalf of Board of Directors

Girdhari Lal Prajapat
Managing Director
DIN : 09513249

Place : Ahmedabad

Date : August 08, 2024

Vipul Gobarbhai Dabhi
Director
DIN : 09513250

Place : Ahmedabad

Date : August 08, 2024

